Table 2. Sample of biologic drugs with pending or past exclusivity dates in the United States48.
| Biologic drug | Original license applicant | FDA approval date |
| Adalimumab | Abbott Laboratories | December 2002 |
| Bevacizumab | Genentech, Inc. | February 2004 |
| Cetuximab | ImClone Systems, Inc. | February 2004 |
| Darbepoetin alfa | Amgen Inc. | September 2001 |
| Epoetin alfa | Amgen Inc. | June 1989 |
| Etanercept | Immunex Corp. | November 1998/September 2004 |
| Filgrastim | Amgen Inc. | February 1991 |
| Infliximab | Janssen Biotech, Inc. | August 1998 |
| Interferon alfa-2b | Schering Corp. | June 1986 |
| Interferon beta-1a | Biogen Idec, Inc. | May 1996 |
| Interferon beta-1b | Bayer Healthcare Pharmaceuticals Inc. | July 1993 |
| Interferon gamma-1b | InterMune, Inc. | February 1999 |
| Pegfilgrastim | Amgen Inc. | January 2002 |
| Peginterferon alfa-2a | Hoffmann-La Roche, Inc. | October 2002/September 2011 |
| Peginterferon alfa-2b | Schering Corp. | January 2001 |
| Rituximab | Genentech, Inc. | November 1997 |
| Trastuzumab | Genentech, Inc. | September 1998 |